Shares of Myriad Genetics (NASDAQ: MYGN) are soaring 5.00% in Monday's intraday trading session following the company's announcement of a significant expansion to its MyRisk® Hereditary Cancer Test. The molecular diagnostic testing leader has added 15 new clinically actionable genes to the test, bringing the total to 63 genes across more than 11 cancer types.

The expanded MyRisk test now includes 100% of the genes strongly recommended by national oncology guidelines, including those from the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO). This enhancement is designed to provide more comprehensive genetic information to guide cancer treatment decisions, surveillance planning, and family risk assessment.

Dale Muzzey, Ph.D., Chief Scientific Officer at Myriad Genetics, emphasized the importance of this expansion, stating, "While many labs can detect DNA variants, it's the interpretation of those variants that truly impacts patient care and that is where Myriad excels." The company's focus on including genes that influence treatment decisions aligns with medical society recommendations, potentially strengthening Myriad's position in the competitive genetic testing market.